New Alzheimer’s Studies Launch at Re:Cognition Health
Re:Cognition Health is delighted to launch two new clinical trials, testing new-generation medications for Alzheimer’s disease.
Our team is passionate about research and education and proud to be spearheading new studies which will test the efficacy of new Alzheimer’s treatments and ultimately working to find a cure for this disease.
This is a randomized, placebo-controlled 12 month Phase 3 clinical trial, which is testing a new medication designed to reduce the elevated levels of abnormal tau protein in the brain, helping to slow down or ideally halt progression of the disease, along with Alzheimer’s symptoms. click here for further information and to register interest in participating.
This clinical trial is testing a new treatment designed to improve symptoms such as cognitive function, sleep, behavioural and psychological symptoms in people with a diagnosis of mild cognitive impairment or Alzheimer’s. This Phase 3 trial will run for a period of 12 months. Click here for further information and to register interest in participating.